Indeed, exogeneous administration of apelin lowered blood glucose levels in normal weight and obese insulin-resistant mice, thereby shedding light at the potential therapeutic implications of apelin in metabolic diseases such as type 2 diabetes mellitus (T2DM). Here, APLN is linked to type 2 diabetes mellitus.